News
The roundtable in Paris was held to explore and exchange views on the science of breakthrough pain management and its related unmet medical needs. On October 4th, Aptar Pharma welcomed a panel of 5 highly renowned speakers specializing in pain management, from Germany, Italy, and the UK: • Dr Sebastiano Mercadante, Professor of Palliative Medicine, University of Palermo, Italy • Dr Ruediger Nave, Associate Principal Pharmacometrics/Pharmacokinetics, Nycomed, Germany • Dr Steve Newman, Scientific Consultant and founder of Ph armaceutical Profiles Ltd, UK • Dr Jonathan Stewart, Consultant Pain Medicine, St Mary’s Hospital, London, UK • Dr Dic Williams, Formerly Research Fellow, Pain Management at Pfizer, UK During this one day meeting, which focused on non-invasive pain management using spray as an alternative to injection and other routes of administration, the experts shared knowledge and debated several key themes, which included: • Optimal pharmacokinetic profiles versus specific pain treatment requirements • Therapy and patients’ needs • Drug formulations, dosing and drug delivery devices • Challenges and opportunities for the future Aptar Pharma and their renowned scientific guests were delighted with the successful outcome of the pain management roundtable. Feedback from the roundtable participants indicated that this meeting provided a number of important insights and answered many questions about pain management. Some of the comments made by the participants were: “Fascinating symposium with an audience from many disciplines which led to many open and interesting scientific discussions.” “Nasal route is a fascinating topic because it is non-invasive and it is surprisingly close to intravenous with regard to pharmacokinetic profile.” “It appears there are many opportunities available in this area of non-invasive pain management.” “Aptar Pharma is very focused on meeting the needs of the pharmaceutical industry as they relate to pain management and we are very pleased to host this roundtable which brought together a panel of experts in this topic.”, said Dr Gerallt Williams, Director Scientific Affairs, Aptar Pharma Prescription Division Aptar Pharma provides a complete range of spray devices for pain management Pain is a major symptom in many medical conditions and can significantly interfere with a patient’s quality of life. Treatment of acute pain episodes includes use of potent prescribed compounds such as triptans for migraine crisis and strong pain killers used post surgery. This treatment also includes the use of controlled substances such as opioids for the management of breakthrough pain episodes experienced by cancer patients. Aptar Pharma develops, manufactures and markets specific spray drug delivery devices for breakthrough pain management as alternatives to the syringe and the needle. These include mechanical multi-dose spray pumps and disposable unit-dose systems as well as electronic devices. Our nasal and sub-lingual/buccal non-invasive delivery devices offer gentle alternatives to injection with potential for rapid onset, reduced dosage leading to reduced side effects, and ease of use without the need for the permanent assistance of a healthcare professional.
Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by years of proven expertise. Aptargroup (NYSE: ATR) is headquartered in the US and has manufacturing sites in North America, Europe, Asia and South America. For more information, visit www.aptar.com.
Elisa Eschylle, Events and Press relations manager Tel.: + 33 (0)1 39 17 20 41 Email : elisa.eschylle@aptar.com Marion Baschet Vernet Tel.: +44 (0)797 609 4100 Email : mbvernet@gmail.com
Download the press release in PDF format < Back